公开(公告)号：US20080132568A1

公开(公告)日：2008-06-05

申请号：US11937351

申请日：2007-11-08

申请人： Todd A. Thompson ,  Debra A. MacKenzie

发明人： Todd A. Thompson ,  Debra A. MacKenzie

IPC分类号： A61K31/277 ,  A61K31/185 ,  A61K31/13 ,  A61K31/135 ,  A61K31/165 ,  A61K31/12 ,  A61K31/095

CPC分类号： A61K31/095 ,  A61K31/12 ,  A61K31/13 ,  A61K31/135 ,  A61K31/165 ,  A61K31/185 ,  A61K31/277

摘要： Compounds having anti-androgenic activities are disclosed. Further disclosed are methods of using the compounds to prevent or treat androgen-dependent diseases or to provide nutraceutical benefits. Pharmaceutical and nutraceutical compositions containing the anti-androgenic compounds are also disclosed.

摘要翻译： 公开了具有抗雄激素活性的化合物。 进一步公开的是使用该化合物来预防或治疗雄激素依赖性疾病或提供营养保健益处的方法。 还公开了含有抗雄激素化合物的药物和营养组合物。

公开(公告)号：US20120277301A1

公开(公告)日：2012-11-01

申请号：US13542432

申请日：2012-07-05

申请人： Todd A. Thompson ,  George Wilding

发明人： Todd A. Thompson ,  George Wilding

IPC分类号： A61K31/353 ,  C12N5/02 ,  A61P35/00

CPC分类号： C07D311/72 ,  A61K31/353

摘要： Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.

摘要翻译： 通过本发明提供了通过施用苯并二氢吡喃衍生的抗雄激素化合物可治疗的雄激素介导的疾病的预防和/或缓解方法。 本发明进一步提供了含有色氨酸衍生的抗雄激素化合物的药物和营养组合物，其用于预防和/或减轻雄激素介导的病症，特别是前列腺癌。

公开(公告)号：US5618291A

公开(公告)日：1997-04-08

申请号：US459790

申请日：1995-06-02

申请人： Todd A. Thompson ,  Tim Kovac

发明人： Todd A. Thompson ,  Tim Kovac

IPC分类号： A61B17/122 ,  A61B17/128 ,  A61B17/28 ,  A61B17/04

CPC分类号： A61B17/1285 ,  A61B17/122 ,  A61B17/128 ,  A61B2017/2929 ,  A61B2017/2948

摘要： A gas-sealed instrument for use in laparoscopic procedures in a gas-insufflated body cavity. The instrument comprises a static portion, a moving portion, and a sealing means for preventing gas from escaping from the body cavity through the static portion. The static portion includes a handle, and an elongate outer tube having a bore, a proximal portion attached to the handle, and a distal portion adapted for inserting into the body cavity. The moving portion includes an operating lever pivotally mounted in the handle, and an elongate operating rod mounted in the bore of the elongate outer tube, and sliding axially relative thereto in response to the operating lever.The sealing means includes a cylinder in the handle and a piston slidably mounted in the cylinder. The cylinder is in gas-tight communication with the bore of the outer tube, and the piston interconnects the operating lever and the operating rod.

摘要翻译： 一种气体密封仪器，用于气体吹入体腔内的腹腔镜手术。 仪器包括静止部分，移动部分和用于防止气体通过静态部分从体腔逸出的密封装置。 静止部分包括手柄和细长的外管，其具有孔，附接到手柄的近端部分和适于插入体腔的远侧部分。 移动部分包括可旋转地安装在手柄中的操作杆和安装在细长外管的孔中的细长操作杆，并且响应于操作杆而相对于其滑动。 密封装置包括手柄中的气缸和可滑动地安装在气缸中的活塞。 气缸与外管的孔气密封连通，活塞将操作杆和操作杆相互连接。

公开(公告)号：US08536219B2

公开(公告)日：2013-09-17

申请号：US13542432

申请日：2012-07-05

申请人： Todd A. Thompson ,  George Wilding

发明人： Todd A. Thompson ,  George Wilding

IPC分类号： A61K31/353

CPC分类号： C07D311/72 ,  A61K31/353

摘要： Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.

摘要翻译： 通过本发明提供了通过施用苯并二氢吡喃衍生的抗雄激素化合物可治疗的雄激素介导的疾病的预防和/或缓解方法。 本发明进一步提供了含有色氨酸衍生的抗雄激素化合物的药物和营养组合物，其用于预防和/或减轻雄激素介导的病症，特别是前列腺癌。

公开(公告)号：US20100022875A1

公开(公告)日：2010-01-28

申请号：US12586927

申请日：2009-09-30

申请人： Michael J. Horzewski ,  Veijo T. Suorsa ,  Todd A. Thompson

发明人： Michael J. Horzewski ,  Veijo T. Suorsa ,  Todd A. Thompson

IPC分类号： A61B8/00

CPC分类号： A61N7/00 ,  A61B90/50 ,  A61B2017/00725 ,  A61B2017/00734 ,  A61B2018/00023 ,  A61N2007/0073

摘要： Systems and methods monitor and enable the use of a medical instrument that is configured to be operated in a prescribed manner. The systems and methods employ a use register sized and configured to be carried by the medical instrument, which comprises a memory field for recording a start date and time at an instance of first operation of the medical instrument. The systems and methods also employ a use monitoring controller, which is adapted and configured to be coupled to the use register. The use monitoring controller includes a start validation function that compares the start date and time to a present real date and time and provides a start validation output based upon the comparison. The use monitoring controller also includes an enablement function that enables operation of the medical instrument only if the start validation output meets prescribed criteria.

摘要翻译： 系统和方法监视和使用被配置为以规定的方式操作的医疗器械的使用。 所述系统和方法采用由医疗器械承载的大小和构造的使用寄存器，其包括用于在医疗器械的第一次操作的情况下记录开始日期和时间的存储区域。 系统和方法还采用使用监视控制器，其被适配和配置为耦合到使用寄存器。 使用监视控制器包括启动验证功能，其将开始日期和时间与当前实际日期和时间进行比较，并且基于比较提供开始验证输出。 使用监视控制器还包括启用功能，只有在启动验证输出满足规定的标准时才能使医疗器械的操作。

公开(公告)号：US20090326055A1

公开(公告)日：2009-12-31

申请号：US12129338

申请日：2008-05-29

申请人： Todd A. Thompson ,  George Wilding

发明人： Todd A. Thompson ,  George Wilding

IPC分类号： A61K31/352 ,  A61P35/00

CPC分类号： C07D311/72 ,  A61K31/353

摘要： The present invention provides methods for inhibiting the growth of androgen-independent prostate cancer tumor cells in a human comprising administering to the human. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived compounds useful in the alleviation of cancer.

摘要翻译： 本发明提供了抑制人中雄激素依赖性前列腺癌肿瘤细胞生长的方法，包括向人施用。 本发明进一步提供含有色素衍生化合物的药物和营养组合物，其可用于缓解癌症。

公开(公告)号：US5800493A

公开(公告)日：1998-09-01

申请号：US429960

申请日：1995-04-26

申请人： Gail Stevens ,  Todd A. Thompson ,  Steven A. Daniel ,  Robert D. Warner

发明人： Gail Stevens ,  Todd A. Thompson ,  Steven A. Daniel ,  Robert D. Warner

IPC分类号： A61B18/04 ,  A61B17/00 ,  A61B17/42 ,  A61B18/08 ,  A61B18/14 ,  A61B19/00 ,  A61M25/00 ,  A61F7/012

CPC分类号： A61B18/08 ,  A61B18/082 ,  A61B17/42 ,  A61B18/1485 ,  A61B2017/00084 ,  A61B2018/00559 ,  A61B2090/064

摘要： An apparatus, and method for endometrial ablation by heating an inflation medium within a distensible bladder positioned within a uterus of a patient. The apparatus comprises an elongate tubular member, a handle, a distensible bladder and a heating element disposed within said distensible bladder. The system includes a controller configured for providing and regulating electric current to the heating element. The controller also includes a pressure sensor for regulating the pressure in the distensible bladder. Pressure and temperature displays and other operator controls are located on the controller unit. The method for performing endothelial ablation comprises inserting the distensible bladder and a portion of the tubular member into a uterus of a patient. The inflation medium within the distensible bladder is heated by providing electric current to the resistive wire of the heating element. The inflation medium within the distensible bladder is heated to a desired temperature and temperature and pressure within the distensible bladder are maintained for a desired time interval. The distensible bladder is then deflated and removed from the uterus.

摘要翻译： 一种用于通过加热定位在患者子宫内的可膨胀囊内的充气介质来进行子宫内膜消融的装置和方法。 该装置包括细长管状构件，手柄，可扩张囊和设置在所述可扩张囊内的加热元件。 该系统包括配置用于向加热元件提供和调节电流的控制器。 该控制器还包括用于调节可膨胀气囊中的压力的​​压力传感器。 压力和温度显示器和其他操作员控制器位于控制器单元上。 用于进行内皮消融的方法包括将可扩张囊和一部分管状构件插入患者的子宫。 通过向加热元件的电阻线提供电流来加热可膨胀囊内的充气介质。 可膨胀囊内的充气介质被加热到所需温度，并且可扩张囊内的温度和压力保持期望的时间间隔。 然后将扩张性膀胱排出并从子宫移除。

公开(公告)号：US08835506B2

公开(公告)日：2014-09-16

申请号：US12990334

申请日：2009-06-05

申请人： Todd A. Thompson ,  Debra Mackenzie ,  Tudor I. Oprea ,  Larry A. Sklar ,  Bruce S. Edwards ,  Mark Haynes

发明人： Todd A. Thompson ,  Debra Mackenzie ,  Tudor I. Oprea ,  Larry A. Sklar ,  Bruce S. Edwards ,  Mark Haynes

IPC分类号： A01N33/02 ,  A61K31/165 ,  A61K31/445

CPC分类号： A61K31/437 ,  A61K31/135 ,  A61K31/165 ,  A61K31/445 ,  A61K45/06 ,  A61N5/10

摘要： A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.

摘要翻译： 治疗和/或预防癌症的方法包括在癌细胞中引起增加的细胞内颗粒度的给药剂，至少足以抑制这些细胞增殖的量，优选以足以导致癌细胞死亡的量。 该方法特别涉及难治性癌症，特别是激素难治性前列腺癌。 所鉴定的试剂导致癌细胞中的细胞内颗粒度增加，并且将粘附的癌细胞转化为非贴壁癌细胞，导致癌细胞死亡。 使用本发明，癌细胞在相对低的药物浓度下经历增加的细胞内粒度，同时也抑制细胞增殖。 增加的浓度导致粘附的癌细胞转化为非粘附的癌细胞，然后转移到细胞死亡。 虽然癌细胞降解和死亡的确切机制尚未完全了解，但治疗的癌细胞（包括难治性前列腺癌细胞）通过自噬机制给予细胞死亡的指示。 还公开了与目前公开的方法相关的药物组合物。

公开(公告)号：US20110224141A1

公开(公告)日：2011-09-15

申请号：US12990334

申请日：2009-06-05

申请人： Todd A. Thompson ,  Debra Mackenzie ,  Tudor I. Oprea ,  Larry A. Sklar ,  Bruce S. Edwards ,  Mark Haynes

发明人： Todd A. Thompson ,  Debra Mackenzie ,  Tudor I. Oprea ,  Larry A. Sklar ,  Bruce S. Edwards ,  Mark Haynes

IPC分类号： A61K31/454 ,  A61K31/496 ,  A61K38/08 ,  A61K31/56 ,  A61P35/00

CPC分类号： A61K31/437 ,  A61K31/135 ,  A61K31/165 ,  A61K31/445 ,  A61K45/06 ,  A61N5/10

摘要： A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.

摘要翻译： 治疗和/或预防癌症的方法包括在癌细胞中引起增加的细胞内颗粒度的给药剂，至少足以抑制这些细胞增殖的量，优选以足以导致癌细胞死亡的量。 该方法特别涉及难治性癌症，特别是激素难治性前列腺癌。 所鉴定的试剂导致癌细胞中的细胞内颗粒度增加，并且将粘附的癌细胞转化为非贴壁癌细胞，导致癌细胞死亡。 使用本发明，癌细胞在相对低的药物浓度下经历增加的细胞内粒度，同时也抑制细胞增殖。 增加的浓度导致粘附的癌细胞转化为非粘附的癌细胞，然后转移到细胞死亡。 虽然癌细胞降解和死亡的确切机制尚未完全了解，但治疗的癌细胞（包括难治性前列腺癌细胞）通过自噬机制给予细胞死亡的指示。 还公开了与目前公开的方法相关的药物组合物。

公开(公告)号：US20100318236A1

公开(公告)日：2010-12-16

申请号：US12797957

申请日：2010-06-10

申请人： John C. Kilborn ,  Matthew Banach ,  Jeffrey L. Clark ,  Todd A. Thompson ,  Gary C. Smith

发明人： John C. Kilborn ,  Matthew Banach ,  Jeffrey L. Clark ,  Todd A. Thompson ,  Gary C. Smith

IPC分类号： G06F1/26

CPC分类号： G06F1/3203 ,  G06F1/189 ,  G06F1/3231 ,  Y02D10/173

摘要： A system for management of workstation energy is provided. The system includes a workstation having an energy outlet operable to provide energy to the workstation, a workstation occupancy sensor disposed in the workstation, and a cluster energy manager coupled with the energy outlet and workstation occupancy sensor. The workstation may be connected in a workstation cluster. The workstation occupancy sensor may be operable to detect occupancy of the workstation. The cluster energy manager may have a distribution circuit configured to control energy provided to the energy outlet, the cluster energy manager operable to control the energy based on occupancy of the workstation and/or a network event. The cluster energy manager is operable to report occupancy or workstation energy consumption to a monitoring system.

摘要翻译： 提供了一种管理工作站能量的系统。 该系统包括具有可操作以向工作站提供能量的能量出口的工作站，设置在工作站中的工作站占用传感器以及与能量出口和工作站占用传感器耦合的集群能量管理器。 工作站可以连接在工作站集群中。 工作站占用传感器可操作以检测工作站的占用。 集群能量管理器可以具有配置成控制提供给能量出口的能量的分配电路，所述集群能量管理器可操作以基于工作站的占用和/或网络事件来控制能量。 集群能量管理器可操作地向监控系统报告占用或工作站能量消耗。